Nuvation Bio's Ibtrozi, an oral medication targeting rare ROS1-positive non-small cell lung cancer mutations, has received FDA approval following promising trial responses and durable remission in brain metastases. Meanwhile, Merck gained FDA approval for Enflonsia (cesrovimab), a monoclonal antibody preventing pediatric respiratory syncytial virus infections. Both approvals underscore advances in targeted therapies addressing unmet clinical needs, with ongoing discussions on treatment positioning amidst regulatory shifts, notably with CDC vaccine advisory committee changes.